Enterprise record

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:0d171594-5056-4796-a2e8-c666d6937243Version: public-1As of: unavailable

22 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 29, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026

    Supports 3 claims
    • Legal Name: Ultragenyx Pharmaceutical Inc. · Claim reviewed: Sep 28, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
    • Published Fact: US · Claim reviewed: Sep 28, 2026

  2. SEC DEF 14A 0001308179-26-000174

    sec def 14a · Source published: Mar 27, 2026 · Retrieved: Sep 12, 2026

    Supports 13 claims
    • Leadership Role: Daniel G. Welch: Independent Chairman of the Board · Claim reviewed: Sep 28, 2026
    • Leadership Role: Amrit Ray, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Corsee D. Sanders, Ph.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Deborah Dunsire, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Emil D. Kakkis, M.D., Ph.D.: President, Chief Executive Officer and Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Shehnaaz Suliman, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Dennis Huang: Chief Technical Operations Officer and Gene Therapy and Executive Vice President · Claim reviewed: Sep 28, 2026
    • Leadership Role: Emil D. Kakkis, M.D., Ph.D.: President and Chief Executive Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Eric Crombez, M.D.: Chief Medical Officer and Executive Vice President · Claim reviewed: Sep 28, 2026
    • Leadership Role: Erik Harris: Chief Commercial Officer and Executive Vice President · Claim reviewed: Sep 28, 2026
    • Leadership Role: Howard Horn: Chief Financial Officer, Corporate Strategy and Executive Vice President · Claim reviewed: Sep 28, 2026
    • Leadership Role: John R. Pinion II: Chief Quality Officer and Executive Vice President of Translational Sciences · Claim reviewed: Sep 28, 2026
    • Leadership Role: Karah Parschauer: Chief Legal Officer & Corporate Affairs and Executive Vice President · Claim reviewed: Sep 28, 2026

  3. DEF 14A lrare2026_def14a.htm

    sec proxy · Source published: Mar 27, 2026 · Retrieved: Sep 2, 2026

    Supports 6 claims
    • Leadership Role: Amrit Ray: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Corsee D. Sanders: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Deborah Dunsire: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Matthew K. Fust: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Michael Narachi: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Shehnaaz Suliman: Director · Claim reviewed: Sep 28, 2026